Do you want to read an article? Please log in or register.
Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial
Therapy and Intervention
Related content
Heart, Artery and Coronary DiseasesMyocardial Infarction
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial
JAMA Cardiol.
Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW
doi: 10.1001/jamacardio.
Therapy and Intervention
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study
J Am Coll Cardiol
Hill JM, Kereiakes DJ, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW
doi: 10.1016/j.jacc.2020.09.603
Heart, Artery and Coronary Diseases
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial
J Am Coll Cardiol.
Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR; EUCLID Trial Executive Committee and Investigators
doi: 10.1016/j.jacc.
Cardiac Arrest or DeathHeart, Artery and Coronary Diseases
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial
JAMA Cardiol
Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, Avezum A, Fox KAA, Berkowitz SD, Bangdiwala SI, Yusuf S, Anand SS
doi: 10.1001/jamacardio.2020.4390
COMMENTED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial
★ 3
Recommended and commented by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1161/CIRCULATIONAHA.120.046524.
Heart, Artery and Coronary Diseases
Effects of Isometric Handgrip Training in Patients With Peripheral Artery Disease: A Randomized Controlled Trial
J Am Heart Assoc.
A Correia M, Oliveira PL, Farah BQ, Vianna LC, Wolosker N, Puech-Leao P, Green DJ, Cucato GG, Ritti-Dias RM
doi: 10.1161/JAHA.119.013596.
Heart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and Stroke
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Lancet.
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators
doi: 10.1016/S0140-
RECOMMENDED
Heart, Artery and Coronary Diseases
Dapagliflozin and Cardiac, Kidney and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation.
Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, Furtado RHM, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS
doi: 10.1161/CIRCULATIONAHA.119.044775.
Heart, Artery and Coronary DiseasesTherapy and Intervention
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial
J Am Coll Cardiol.
Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators
doi: 10.1016/j.jacc.2017.10.010.